cabergoline has been researched along with ganirelix in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Amols, MH; Coddington, CC; Hudson, SBA; Rollene, NL | 1 |
| Balayla, J; Dahan, MH; Shrem, G; Son, WY; Steiner, N; Tannus, S; Volodarsky-Perel, A | 1 |
1 review(s) available for cabergoline and ganirelix
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cabergoline and ganirelix
| Article | Year |
|---|---|
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
Topics: Adult; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Gonadotropin-Releasing Hormone; Humans; Ovarian Hyperstimulation Syndrome; Treatment Outcome | 2009 |
Use of cabergoline and post-collection GnRH antagonist administration for prevention of ovarian hyperstimulation syndrome.
Topics: Adult; Buserelin; Cabergoline; Dopamine Agonists; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Retrospective Studies | 2019 |